Crescent Biopharma, Inc. (NASDAQ:CBIO) Given Average Recommendation of “Buy” by Analysts

Shares of Crescent Biopharma, Inc. (NASDAQ:CBIO) have been assigned an average rating of “Buy” from the nine ratings firms that are covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, five have issued a buy recommendation and three have given a strong buy recommendation to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $28.00.

CBIO has been the subject of several research reports. Wall Street Zen lowered shares of Crescent Biopharma from a “hold” rating to a “sell” rating in a research report on Saturday, January 31st. Stifel Nicolaus set a $29.00 price target on shares of Crescent Biopharma in a research note on Thursday, February 26th. Weiss Ratings reiterated a “sell (e-)” rating on shares of Crescent Biopharma in a research note on Monday, December 29th. Piper Sandler started coverage on Crescent Biopharma in a research report on Wednesday, January 28th. They issued an “overweight” rating and a $35.00 target price for the company. Finally, HC Wainwright lowered their target price on Crescent Biopharma from $25.00 to $22.00 and set a “buy” rating on the stock in a research note on Monday.

Trending Headlines about Crescent Biopharma

Here are the key news stories impacting Crescent Biopharma this week:

• Positive Sentiment: HC Wainwright sharply reduced the magnitude of its loss forecasts for FY2026 and each quarter (Q1–Q4 2026 EPS revised to ~?$0.76 to ?$0.81 and FY2026 to ?$3.14 from a prior much larger loss), and keeps a “Buy” rating with a $22 price target — a near?term catalyst supporting upside expectations. Read More.
• Positive Sentiment: Crescent expanded its oncology collaboration footprint via an alliance with Kelun?Biotech to advance bispecific/ADC combination strategies — this partnership could enhance the company’s pipeline value and future partnering or licensing opportunities. Read More.
• Neutral Sentiment: Short?interest reports for early March show anomalous values (0 shares, NaN changes, days?to?cover 0.0) — appears to be a data/reporting error, so there’s no clear evidence of a rising short burden or squeeze risk from the published figures.
• Negative Sentiment: A recent writeup framed HC Wainwright commentary as pessimistic for CBIO’s near?term share price (headline suggests negative outlook), which can amplify selling, especially after the company’s prior large quarterly EPS miss. Read More.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of CBIO. ADAR1 Capital Management LLC bought a new position in shares of Crescent Biopharma in the fourth quarter worth $7,187,000. Vestal Point Capital LP purchased a new position in Crescent Biopharma during the 4th quarter valued at about $17,790,000. Tang Capital Management LLC lifted its holdings in shares of Crescent Biopharma by 28.3% in the fourth quarter. Tang Capital Management LLC now owns 872,398 shares of the biopharmaceutical company’s stock worth $10,347,000 after buying an additional 192,574 shares in the last quarter. Quadrature Capital Ltd bought a new position in shares of Crescent Biopharma in the fourth quarter valued at approximately $157,000. Finally, RTW Investments LP bought a new position in shares of Crescent Biopharma in the fourth quarter valued at approximately $4,422,000. 75.19% of the stock is currently owned by hedge funds and other institutional investors.

Crescent Biopharma Stock Performance

Shares of CBIO stock opened at $11.33 on Friday. The company has a market capitalization of $157.37 million, a price-to-earnings ratio of -0.80 and a beta of 1.31. Crescent Biopharma has a 52-week low of $8.72 and a 52-week high of $28.77. The company has a 50-day simple moving average of $11.19 and a two-hundred day simple moving average of $12.37.

Crescent Biopharma (NASDAQ:CBIO) last released its earnings results on Thursday, February 26th. The biopharmaceutical company reported ($4.01) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.22) by ($1.79). The firm had revenue of $10.84 million during the quarter. On average, sell-side analysts forecast that Crescent Biopharma will post -0.16 EPS for the current fiscal year.

About Crescent Biopharma

Crescent Biopharma, Inc (NASDAQ: CBIO) is a clinical?stage immuno?oncology company focused on the discovery, development and commercialization of novel therapies for patients with solid tumors. The company’s research strategy centers on combination approaches that enhance anti?tumor immune responses by simultaneously targeting multiple pathways implicated in immune evasion and tumor growth.

The company’s lead candidate, CPB-201, is a bifunctional fusion protein designed to block programmed death-ligand 1 (PD-L1) while neutralizing transforming growth factor-beta (TGF-?), with the goal of restoring T-cell activity and reducing tumor fibrosis.